Elafi n, an endogenous serine protease inhibitor, modulates colonic infl ammation. We investigated the role of elafi n in celiac disease (CD) using human small intestinal tissues and in vitro assays of gliadin deamidation. We also investwigated the potential benefi cial effects of elafi n in a mouse model of gluten sensitivity.
INTRODUCTION
Celiac disease (CD) is triggered by the ingestion of gluten in genetically susceptible individuals. Gluten has been proposed to contribute to health issues other than CD ( 1 -4 ) . Currently, there are no pharmacological treatments available for patients with CD or other gluten-related disorders. A life-long adherence to a gluten-free diet (GFD) is required aft er the diagnosis of CD is confi rmed. However, a GFD is associated with high nonadherence rates ( 5, 6 ) . Gluten is a common ingredient in many food items, making complete removal of gluten from the diet challenging ( 7, 8 ) . Although eff ective in inducing clinical remission of CD, following a strict GFD may have a negative impact on lifestyle and quality of life ( 9 -11 ) .
Elafi n is a human serine protease inhibitor that has potent inhibitory capacity against various forms of elastases, as well as proteinase-3 ( 12 -14 ) . Elafi n is expressed throughout the epithelium of the gastrointestinal tract, and its expression and induction is decreased in patients with infl ammatory bowel Novel Role of the Serine Protease Inhibitor Elafi n in Gluten-Related Disorders disease ( 15 -17 ) . However, it is unknown whether elafi n expression is altered and whether it has a role in chronic infl ammatory disorders of the proximal small intestine, such as CD.
Elafi n has been identifi ed as a substrate for the cross-linking activity of tissue transglutaminase (TG-2) ( 18, 19 ) . Th e discovery that TG-2 has an important role in CD by introducing negatively charged residues in gluten peptides through deamidation, thereby increasing binding affi nity to HLA-DQ2 / DQ8 molecules, is one of the recent milestones in CD pathogenesis ( 20 ) . Given the importance of TG-2 to the pathogenesis of CD, its inhibition is an attractive therapeutic target. TG-2, however, is found systemically and has important functions in a number of other biological processes including wound healing, cell migration, cell death, and infl ammation ( 21 ) . Whether the inhibition of TG-2 is reversible and local to the small intestine are important considerations for a CD-targeted therapy. Th e ability of elafi n to inhibit deamidation of gliadin peptides by TG- 2 has not yet been tested. Th e small intestinal expression profi le of this immunomodulatory protease inhibitor is unknown in CD. Th us, we fi rst investigated the expression of elafi n in patients with active CD and 1 year aft er a GFD. Patients undergoing gastroduodenal endoscopy, in whom CD was excluded, were included as controls. Th e potential interaction of elafi n and human TG-2, an enzyme with an established role in CD pathogenesis, was tested using 33-mer peptide deamidation assays. Finally, the anti-infl ammatory and barrier-enhancing properties of elafi n in the proximal small intestine were investigated in an animal model of gluten sensitivity.
METHODS

Elafi n expression in human small intestinal mucosa
Human small intestinal biopsies used in this study were randomly selected from a series of subjects participating in previous studies ( 22, 23 ) . Th e baseline clinical characteristics of subjects are shown in Table 1 . Th e CD diagnosis was based on the concomitant presence of histological damage in the fi rst and second duodenal portions (Marsh IIIa or greater) and a positive CD serology (IgA anti-TG-2; Inova, San Diego, CA). Histology was investigated in biopsy specimens of patients at the time of the diagnosis ( n = 10), in the same patients aft er 1 year of a GFD ( n = 9), and in patients with dyspepsia, peptic ulcer, gastroesophageal refl ux disease, or irritable bowel syndrome , where the diagnosis of CD was excluded ( n = 11).
Five-micrometer sections were deparaffi nized and treated with a buff er solution for heat-induced epitope retrieval (pH 6.0). Slides were incubated overnight at 4 ° C with anti-elafi n (Santa Cruz Biotechnology, Montrouge, France) and anti-cytokeratin 18 (CK18; Santa Cruz Biotechnology) antibodies. Anti-CK18 was used as a marker for epithelial cells. Slides were mounted and nuclei were stained with 4 ′ ,6-diamidino-2-phenylindole (DAPI) fl uorescent mounting medium (Invitrogen, Burlington, ON, Canada) and analyzed on confocal microscope Zeiss LSM710 (Carl Zeiss, Toronto, ON, Canada). For relative quantifi cation by immunofl uorescence staining, four diff erent fi elds of acquisitions for one patient were taken with the same microscope settings in a blinded manner. We have converted images from mucosal epithelial marker (CK18) to a binary mask in order to obtain a fi nal image representing only the specifi c staining of elafi n in the mucosa. Elafi n fl uorescence intensity was then quantifi ed in this image using the Image J soft ware (National Institutes of Health, Bethesda, MD) and was reported as arbitrary unit per surface of tissue. Each plot represents the mean fl uorescence intensity (MFI) of four diff erent acquisition fi elds of the same patient. Data were represented as fold increase of signal intensity quantifi ed in control patients.
Inhibition of deamidation of 33-mer peptide by elafi n
Th e 33-mer peptide (25 μ M, alpha2-gliadin, 33mer (aa 56-88), Zedira, Darmstadt, Germany, diluted in 50 mM phosphate buff er, pH 7.5) was incubated with 1 μ M TG-2 (0.59 U / mg, purity > 90 % , Zedira) at 37 ° C in 100 mM Tris / HCl buff er, pH 7.6, with 10 mM CaCl 2 . Th e TG-2-catalyzed deamidation of 33-mer served as a control reaction in the assay. In the competitive reaction, 25, 50, and 100 μ M elafi n (human, recombinant, purity > 90 % , SigmaAldrich, St. Louis, MO) was mixed with the peptide before starting the enzymatic reaction. A negative control with insulin (human, recombinant, purity > 98 % , Sigma-Aldrich) and a positive control with tridegin (recombinant, purity > 95 % , Zedira) were prepared each in a 1:1 molar ratio with the 33-mer peptide . Th e reaction was inactivated at diff erent time points (0, 5, 15, 30, 60 min) by the addition of 25 mM iodoacetamide. All reactions were performed in triplicate. Th e analysis of the samples was performed using a liquid chromatography system consisting of Rheos Allegroquaternary pump, C18-column (Hypersil Gold, 100 × 1 mm, 1.9 μ m), and XCalibur control soft ware (Th ermo Fisher Scientifi c, San Jose, CA). Samples were injected (10 μ L) with a fl ow rate of 50 μ Lmin, 95 % water ( + 0.1 % v / v formic acid) as an initial value for 1 min, followed by a linear gradient of ACN ( + 0.1 % v / v formic acid) over 19 min (95 -5 % v / v). Th e liquid chromatography was directly connected to an LTQ XL linear quadrupole Ion Trap (Th ermo Fisher Scientifi c) equipped with an electrospray ion source. Data were acquired by full mass spectrometry. Given that deamidation yields in a mass increase of 1 Da only, the untreated and deamidated peptide overlap in the ( 24 ) . Th e total deamidation degree was determined by calculating the diff erence of centroid masses of TG-2-reacted and untreated peptide.
Animal model of gluten sensitivity
Eight-to 10-week-old male NOD AB ° DQ8 (NOD / DQ8) transgenic mice were used for experiments ( 25 ) . Mice were weaned and maintained on a low-fat (4.4 % ), GFD, purchased from Harlan Laboratories (Indianapolis, IN) and bred in a conventional, specifi c pathogen-free colony at McMaster University. All experiments were conducted with approval from the McMaster University Animal Care Committee.
Mice were orally sensitized with a peptic-tryptic digest of gliadin (PT-gliadin), prepared as described previously ( 26 ) . Mice were gavaged with 500 μ g of PT-gliadin plus 25 μ g of cholera toxin (Sigma-Aldrich) once per week for 3 weeks ( 27 ) . Nonsensitized controls were gavaged with 25 μ g cholera toxin only. Aft er sensitiza-(1) (1) tion, mice were challenged with gliadin (2 mg / mouse) dissolved in 0.02 M acetic acid by intragastric gavage once a week for 2 weeks.
Mucosal delivery of elafi n
We chose a L. lactis vector as mucosal delivery system for elafi n, as this approach was extensively validated in previous mouse models of colitis ( 17 ) . Briefl y, an elafi n-producing recombinant strain of L. lactis was used as a bacterial vector to deliver elafi n to the intestine. L lactis carrying the empty plasmid vector ( Ll -WT) was used as a wild-type (WT) control ( 17 ) . All bacteria were suspended in PBS containing 15 % glycerol. Twenty-four hours aft er oral sensitization with PT-gliadin and cholera toxin, NOD / DQ8 mice were treated with Ll-WT, Ll-E (10 9 colony forming units ), or PBSglycerol by oral gavage, daily for 15 days. Mice received gliadin challenges (2 mg / mouse) on days 7 and 15 of L. lactis treatment.
Measurement of small intestinal permeability
Twenty-four hours following the fi nal gliadin challenge, in vitro intestinal permeability was assessed by the Ussing chamber technique, as previously described (World Precision Instruments, Sarasota, FL) ( 27 -29 ) . Two sections of jejunum from each mouse were assessed. Tissue conductance (the passive permeability to ions) and mucosal-to-serosal fl ux of the paracellular probe 51 Cr-EDTA were used to assess barrier function and para cellular permeability, as previously described ( 30 ) . 51 Cr-EDTA fl ux was calculated as the average over a 2-h period and expressed as % hotsample / h / cm 2 .
Evaluation of small intestinal infl ammation
Cross-sections of the proximal small intestine were fi xed in 10 % buffered formalin, embedded in paraffi n, and stained with hema toxylin and eosin for histologic evaluation by light microscopy (Olympus, Richmond Hill, ON, Canada), as previously described ( 27 ) . Paraffi n sections were used to preserve tissue morphology and orientation.
Immunostaining for CD3 + cells was performed on paraffi n sections to detect the presence of intraepithelial lymphocytes (IELs) in sections of the proximal small intestine, as described previously ( 29, 31 ) . Slides were viewed in a blinded manner by light microscopy under × 20 magnifi cation. IELs per 20 enterocytes in fi ve randomly chosen villus tips were counted according to the previously described methods and expressed as IEL / 100 enterocytes ( 29 ) .
ZO-1 expression in small intestine
Staining for the tight-junction protein zonula occludens-1 (ZO-1) was performed on jejunal sections. Sections were incubated for 2 h at room temperature with an anti-ZO-1 (primary) antibody (Invitrogen), washed, and secondary antibody was applied for 2 h at room temperature. Slides were then mounted and coverslipped with Prolong Gold Anti-fade with DAPI (Invitrogen), and staining was assessed in a blinded manner by using a fl uorescence microscope (Olympus). A total of 10 images were obtained for each slide, and the MFI of fi ve identically sized regions of interest was determined for each image using the Image J Soft ware (National Institutes of Health). Each region of interest was centered on the epithelial border. Th e MFI for the negatively stained sections was then subtracted from that of positively stained sections.
Trypsin-like and elastase-like activities in the small intestine
A section of the jejunum from nonsensitized and sensitized NOD / DQ8 mice ( n = 5) was collected using a 4-mm biopsy punch and transferred into a 48-well plate (BD Biosciences, Mississauga ON, Canada) containing RPMI 1640 enriched with 10 % FBS, 100 U / ml penicillin, 100 U / ml streptomycin, and 2 mM L-glutamine. Wells were supplemented with 100 μ g / ml of one the following gliadin peptides: 19-mer (p31-49), 20-mer (p120-139), and 33-mer (p56-89; ProImmune, Sarasota, FL). Media alone were used for negative controls. Plates were incubated for 3 h at 37 ° C with 95 % O 2 and 5 % CO 2 . Aft er incubation, the tissue section was removed and frozen at − 80 ° C. Supernatants were collected and stored at − 80 ° C. Trypsin and elastase-like activity was measured in organ culture supernatant, biopsies, as well as intestinal samples from nonsensitized and gliadin-sensitized mice, as previously described ( 32 ) .
Statistical analysis
Statistical analysis was conducted using the GraphPad Prism soft ware (version 4, 2004, GraphPad Soft ware Inc., San Diego, CA). Statistical signifi cance was determined by one-way analysis of variance followed by Bonferroni ' s multiple comparison tests. Signifi cance was reported for P values < 0.05 at a 95 % confi dence level. All data are presented as mean ± s.e.m.
RESULTS
Elafi n expression is reduced in the small intestine of patients with active CD
We tested whether elafi n expression is altered in small intestinal biopsies of patients with CD. Biopsies were collected from the duodenum and jejunum of patients with active CD (on a glutencontaining diet), treated CD patients (on a GFD for at least 1 year), and control patients (gastrointestinal complaints in which CD has been excluded). Biopsies were then stained for elafi n expression by immunofl uorescence. Elafi n expression in the epithelium, as determined by co-staining with CK18, was lower in patients with active CD compared with control patients ( Figure 1a ). Th is reduction was confi rmed by determining the MFI of elafi n expression in areas of tissue staining with the CK18 marker. Elafi n intensity was signifi cantly lower in active CD patients compared with control patients ( Figure 1b ). Elafi n levels in treated CD were 
Ll -elafi n reduces gliadin-induced IEL infi ltration in gliadinsensitized NOD / DQ8 mice
We then tested the therapeutic potential of elafi n in gliadin-sensitized NOD / DQ8 mice, a mouse model of gluten sensitivity, using L. lactis to deliver elafi n ( Ll -E) to the small intestine. In agreement with previous fi ndings, ( 5, 27 ) sensitization and acute gliadin challenge increased IELs in the jejunum ( Figure 3 ). Ll -E treatment normalized IEL counts, whereas Ll -WT had no eff ect ( Figure 3 ).
Ll-elafi n reduces intestinal barrier dysfunction and preserves ZO-1 distribution following gliadin challenge in sensitized NOD / DQ8 mice.
Gliadin sensitization and acute gliadin challenge increased small intestinal paracellular permeability, as indicated by increased in vitro 51 Cr-EDTA fl ux in NOD / DQ8 mice ( Figure 4a ). Gliadin challenge in sensitized mice also increased tissue conductance ( Figure 4b ). Sensitized mice treated with Ll -E had lower intermediate between untreated CD and controls but were not statistically diff erent from either.
Inhibition of deamidation of 33-mer peptide in vitro
Elafi n has been identifi ed as a substrate for TG-2 ( 19 ) . Using a competitive enzymatic assay, we therefore tested elafi n ' s inhibiting eff ect on the deamidation of 33-mer gliadin peptide, which served as a model immunogenic substrate. Th e addition of elafi n signifi cantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form ( Figure 2 ) . Th e inhibiting eff ect of elafi n was found to be dose and time-dependent, but relatively modest compared with tridegin, the positive control ( 33 ) . When used at a concentration that was 4-fold higher than tridegin, the deamidation of the 33-mer peptide was approximately 50 % less eff ective aft er 30 min of incubation. As expected, the negative protein control, insulin, did not show any inhibition of TG-2 activity ( Figure 2 ). Cr-EDTA fl ux and tissue conductance compared with sensitized animals receiving either PBS -glycerol or Ll -WT ( Figure 4a and b ) .
We investigated a previously unexplored eff ect of elafi n on ZO-1 distribution in the small intestine of gluten-sensitive mice. Staining for ZO-1 was decreased in gliadin-sensitized mice compared with controls. Th e expression of ZO-1 was patchy, with most of the expression being limited to the villus base and crypts. Th e distribution of ZO-1 normalized in sensitized mice treated with Ll -E ( Figure 4c ). We confi rmed this reduction in ZO-1 staining by determining the MFI ( Figure 4d ). Sensitized animals treated with PBS -glycerol had signifi cantly lower ZO-1 MFI than nonsensitized controls. Treatment of sensitized animals with Ll -E normalized ZO-1 MFI ( Figure 4d ).
Gliadin challenge does not affect small intestinal trypsin-like or elastase-like proteolytic activity
To investigate the potential mechanisms of action of elafi n, we measured trypsin-and elastase-like activity in small intestinal tissues from sensitized and nonsensitized NOD / DQ8 mice treated with PBS, LI -WT, or LI -E . Th e levels of trypsin-like proteases were similar in sensitized and nonsensitized mice, and they were not aff ected by elafi n treatment ( Figure 5a ). Elastaselike activity was undetectable (data not shown). Proteolytic activity was also tested in small intestinal tissue from nonsensitized and sensitized mice stimulated in vitro with the gliadin peptides 33-mer, 20-mer, and 19-mer. Elastase-like activity was undetectable (data not shown) and trypsin-like activity was has substantially risen in the past two decades ( 34, 35 ) . Th e only treatment is a life-long adherence to a GFD, which is costly and diffi cult to follow, leading to high nonadherence rates ( 6 ) . In CD, gluten-derived peptides are recognized by HLA-DQ2 or HLA-DQ8 heterodimers on antigen-presenting cells, which trigger a proinfl ammatory gluten-specifi c T-cell response ( 36 ) . Th rough the process of deamidation, TG-2 activity has an important role by introducing negatively charged residues on gluten peptides. Th is enhances recognition of these gluten peptides by the HLA-DQ2 or − DQ8 molecules, which are efficiently recognized by T cells ( 36, 37 ) . However, the factors that drive TG-2 activation in patients with CD are not completely understood ( 37, 38 ) . Elafi n is a potent endogenous human serine protease inhibitor, and its levels have been found to be reduced in the colon of patients with infl ammatory bowel disease (IBD) ( 15, 17 ) . In this study, we show that patients with active CD also have reduced elafi n expression within the small intestinal epithelium compared with patients in whom CD was excluded. Aft er 1 year of GFD, elafi n expression was somewhat higher than in active CD patients, but was not statistically diff erent from nonceliac controls. Th e reduced elafi n expression in patients with active CD may refl ect the presence of enteropathy, and its loss may contribute to enhanced infl ammation in CD. In fact, expression of other enzymes in the small intestine, such as cytochrome P450, CYP3A, was found to correlate with the degree of enteropathy, raising the possibility of using these markers as an indication of villous health ( 39, 40 ) . Reduced expression of elafi n in patients with active CD may refl ect activity of infl ammation or mucosal damage in the small intestine, similar to what has been described in the colon of patients with IBD ( 15 -17 ) .
We then hypothesized that elafi n may have a role in glutenrelated disorders and tested the interaction of elafi n with human TG-2, the enzyme that catalyzes the deamidation of gluten peptides enhancing T-cell recognition ( 36 ) . Indeed, elafi n has recently been identifi ed as a substrate for the cross-linking activity of tissue transglutaminase ( 19, 41, 42 ) . Our in vitro results demonstrate that the addition of elafi n inhibited the deamidation of the digestionresistant 33-mer gliadin peptide, which is one of the potential triggers of the adaptive immune response in CD ( 43 ) . Th e comparison of elafi n to tridegin, a known transglutaminase inhibitor, revealed that elafi n moderately inhibits TG-2. Th ese data support that elafi n interacts with TG-2, raising the possibility that in addition to correlating with mucosal damage a reduction of elafi n in active CD could have a pathogenic role. TG-2 has important roles in tissue homeostasis and wound healing ( 21, 44 ) . Th us, the moderate inhibition and small intestinal delivery of elafi n could constitute an advantage over systemic, complete, and irreversible inhibition, particularly when combined with other potential benefi cial eff ects of elafi n. Our in vitro results point at an exciting novel role and specifi c mechanism of action of elafi n in CD that should be further explored.
Elafi n has been shown to have anti-infl ammatory and barriermodulating properties in models of respiratory, cardiovascular, and colonic infl ammation ( 17,32,41,45 ) . We explored whether not signifi cantly aff ected in either the small intestinal biopsies or culture supernatant following in vitro stimulation with the gliadin fragments ( Figure 5b and c ) .
DISCUSSION
CD is one of the most common gastrointestinal diseases, aff ecting about 1 % of the Caucasian population, and its incidence 
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Elafin and Celiac Disease elafi n administration aff ected these parameters in the small intestine using a model of gluten sensitivity. We used a validated delivery method that exploits a food-grade strain of L. lactis , to ensure administration of elafi n to the gastrointestinal tract in mice ( 17, 32 ) . Although the quantifi cation of elafi n delivered to the intestine was not determined, using GFP-tagged Ll -WT and Ll-E, we have previously demonstrated eff ective delivery of L. lactis and elafi n to the gastrointestinal tract. Elafi n was found to cluster around L.lactis , but was also detected at sites remote from the GFP-tagged L. lactis , suggesting that elafi n is secreted in the mucosa in situ ( 17 ) . We found that Ll -E reduced intraepithelial lymphocytosis and restored barrier function in gliadin-sensitized mice. We showed that treatment with Ll -E normalized 51 Cr-EDTA fl ux and conductance in the small intestine, suggesting that Ll -E protects the paracellular pathway in the small intestine. Furthermore, increased permeability aft er gliadin challenge was accompanied by a reduction in ZO-1 protein expression, and Ll -E therapy preserved ZO-1 protein distribution in sensitized mice. Overall, our results suggest that there are benefi cial eff ects of Ll -E in this model of gluten-induced small intestinal dysfunction that involve immunomodulatory eff ects and regulation of barrier and tight-junction function. Th is is consistent with previous reports on the eff ect of elafi n in the colon using animal models of colitis ( 14, 17, 32 ) . Proteolytic imbalances have been described in patients with irritable bowel syndrome, IBD, and in animal models of experimental colitis ( 17, 32 ) . However, we found no diff erences in trypsin or elastase-like activity between gliadin-sensitized and control mice. In addition, treatment with Ll -E had no eff ect on small intestinal protease levels. Our fi ndings highlight a diff erence in the mechanisms of action of elafi n in gluten intolerance compared with colitis, which does not involve correction of elastolytic or trypsin activity imbalance in the small intestine.
Although the NOD / DQ8 mouse model does not develop severe atrophy that is characteristic of classical CD, sensitization and challenge induce moderate infl ammation ( 27 ) . It will be important to test the eff ect of elafi n, as well as other potential therapies for CD, in a variety of models of gluten sensitivity that express diff erent pathological characteristics and underlying mechanisms, such as IL-15-driven models of CD ( 46 ) .
In conclusion, the reduced small intestinal elafi n expression in patients with active CD, coupled to the fi nding that elafi n may compete with gliadin peptides and reduce their deamidation, raise the possibility that loss of this protease inhibitor contributes to CD pathogenesis. Th e results in the animal model of gluten sensitivity suggest that mucosal delivery of elafi n restores small intestinal barrier function and infl ammation, likely through preservation of tight-junction function and anti-infl ammatory eff ects in the small intestine. Owing to the combination of specifi c and nonspecifi c benefi cial eff ects of elafi n in our study, we propose that its replacement could have potential as adjuvant therapy in gluten-related disorders.
